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ditorialuest editor’s introduction for BDQ special issue: ‘Advanced
olecular Diagnostics for Biomarker Discovery’ear reader,
I have thehonour to present theﬁrst special issue in ‘Biomolecu-
arDetection andQuantiﬁcation’ (BDQ)which is entitled ‘Advanced
olecular Diagnostics for Biomarker Discovery’. It is published
n conjunction with the last qPCR and NGS 2015 event which
ook place in March 2015 in Freising Weihenstephan, Germany
www.qPCR-NGS-2015.net) covering the same theme. This aim
f this special issue is to present the newest developments in
ighly sophisticated molecular techniques and related scientiﬁc
pplications in combination with the latest data analysis tools.
urthermore, the implementation of these advanced molecular
iagnostics tools for discovery, quantiﬁcation and validation of
olecular biomarkers will be presented. Since 2004 the history
f this conference series was primarily focused on quantitative
CR (qPCR) related techniques and applications, but since 2010
he focus was broadened to digital PCR (dPCR), next generation
equencing (NGS) and the underlying complex data analysis apply-
ng bioinformatical tools. This history is nicely summarized by the
DQ editors in one of the previous editorials ‘qPCR, dPCR, NGS – A
ourney’ [1].
Today, biomarkers have immense scientiﬁc and potential clin-
cal value in the diagnostic testing pipeline. They span the broad
iagnostic sector from the genome to the phenome over various
-ome’ levels and have been used since the earliest days of the
pplication of molecular biology. A biomarker signature is capable
f revealing speciﬁc biological traits or measurable physiological
hanges, according to a disease status, physiological or patholog-
cal condition, or after drug application [2]. As novel gene-based
iagnostics proliferate, they will be increasingly important to drug
evelopment, approval and later in clinical practice. There are
umerous promising singular biomarkers or more complex multi-
lebiomarker signatures available, themost importantofwhichare
urrently used for assessing drug development, patient stratiﬁca-
ionormeasuring theefﬁcacyof treatment in therapeuticmedicine.
learly there is a translation problem to transfer the results from
olecular diagnostics research to drug development and ﬁnally
linical practice [3,4]. In future, biomarkers and their interaction
n various ‘-ome’ levels will increase the molecular and cellular
nowledge of disease and drug mechanisms.
The ﬁrst goal in the biomarker development pipeline is the
eneration of reliable biological data from applied diagnostic tech-
iques and applications. Therefore, an international consortium of
ttp://dx.doi.org/10.1016/j.bdq.2015.09.003
214-7535/© 2015 Published by Elsevier GmbH. This is an open access article under the Cscientists, working in various ﬁelds of nucleic acidsmolecular diag-
nostics established working guidelines for qPCR and dPCR [5,6].
These, so called, MIQE guidelines have set new standards in clini-
cal, veterinary and agricultural diagnostics science and are highly
appreciated by the scientiﬁc community, which is evident by the
high citation rate of these publications.
An important step in the workﬂow of molecular diagnostics
and biomarker development is driven by tissue limitations and
the relatedmethodological considerations. Therefore the ﬁrst focus
of the presented publications is dedicated to nucleic acid degra-
dation and the impact of RNA quality and RNA integrity to ensure
transcriptional biomarker validity andhow post-mortem and physical
degradation affects RNA stability. A furtherMIQE compliant publica-
tion is focused on the optimization of the qPCR workﬂow and data
analysis by removal of between-run variation in a multi-plate qPCR
experiment.
Novel classes of biomarkers are circulating nucleic acids which
are free ﬂoating in blood, bound to proteins or coating cellular
micro-vesicles.Most prominent is themicroRNA family,whichwas
recently detected as free, extracellular RNA in the bloodstream
[7]. Their potential application as circulating biomarkers in ‘liquid
biopsies’ was promptly recognized and investigated, because they
are capable of distinguishing diseased individuals from healthy
probands. The non-invasive nature of circulating microRNA collec-
tion and their sensitivity and speciﬁcity in diseases has encouraged
intensive microRNA biomarker research. Since then, circulating
extracellular small RNAs (smexRNA) have been detected in a vari-
ety of body ﬂuids, e.g. milk, saliva, tears, sweat, cerebrospinal ﬂuid,
urine, etc. [8]. Herein we present the potential of smexRNA in vet-
erinary diagnostics to serve as new biomarker signatures by applying
multivariate data analysis.
A further focus in this special issue ‘Advanced Molecular Diag-
nostics for Biomarker Discovery’ is dedicated to high throughput
genomics and transcriptomics technologies by applying NGS tech-
niques. This advanced technology potentially allows a holistic view
andgeneratesnumerous candidatebiomarkerswithpotential diag-
nostic or clinical value, but the practical value of these broadly
scattered biomarkers remains uncertain. The implementation of
the NGS workﬂow into the clinic is challenging, due to insufﬁcient
control for variation in patient sample loading, target ampliﬁcation
efﬁciency, librarypreparationand later sequencingerror.Oneof the
publications in this special issue addresses these methodological
considerations in theNGSworkﬂow– control for stochastic sampling
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ariation and the polymerase error. In the recent years, time consum-
ng Sanger sequencing has been increasingly replaced by parallel
esequencing of multiple genes using NGS technologies. Molecu-
ar diagnostic laboratories or commercial vendors often develop
ustomized NGS resequencing workﬂows for speciﬁc diagnostic
ortfolios. Herein the application of a new target enrichment strat-
gy is presented, enabling the resequencing of any human genomic
egion of interest by targeted resequencing and variant validation
sing ‘pxlence’ PCR assays.
While the quality of the sample to be investigated is an impor-
ant consideration, sample availability is often limited. Hence, in
uman diagnostics there is always the challenge to detect numer-
us biomarkers from limited sample material. Taking this to the
xtreme, we are able to sample single cells, such as circulating
umor cells (CTCs), and quantify the cellular nucleic acid con-
ent. One of the special issue publications focusses on this area of
esearch, exploring the feasibility of a protocol for the isolation and
olecular characterization of single CTCs from cancer patients using a
ingle-cell NGS approach.
A further source of variance in samplemeasurement is the intro-
uction of pre-ampliﬁcationmethods tomake the essential nucleic
cid biomarkers measurable with such limited starting material.
his topic is addressed in a contribution on the evaluation of bias
ssociated with high-multiplex and target-speciﬁc pre-ampliﬁcation.
To achieve reproducible diagnostic signatures and physiological
eaningful answers, various complex bioinformatical tools have
o be applied for data analysis. The integrative analysis of mul-
ilevel biological markers, most prominent the microRNA–mRNA
etwork, and additionally the analysis of genomic, proteomic,
r metabolomic markers will help to understand the molecular
nteraction between the ‘-ome’ levels, and hence the impact on
hysiology. By using sophisticated bioinformatic tools to integrate
ingular biomarker datasets, one can identify regulatory networks
n the post-transcriptional level and even beyond [9]. These regu-
atory networks and the connected biomarkers help to understand
he disease processes, the interactionwith drugs andwill be essen-
ial to shape meaningful clinical conclusions. Thus, the use of
iomarker signatures and the connected molecular network, and
heir successful translation into clinical practice are likely to play an
mportant role indeveloping andpromotingpersonalizedmedicine
n the near future.I hope the selection of the presented publications in this ﬁrst
DQ special issue ‘Advanced Molecular Diagnostics for Biomarker
iscovery’ has attracted your attention and will help to solve fur-
her analytical challenges in your own biomarker developmentd Quantiﬁcation 5 (2015) 1–2
pipeline. You can watch a selection of recorded talks presented at
the qPCR andNGS 2015 symposium in Freising-Weihenstephan via
our streamingportal eConferences – Amplify your knowledge in qPCR,
dPCR and NGS! (eConference.qPCR-NGS-2015.net). This streaming
portal is dedicated to scientists from the community of qPCR, dPCR,
NGS, and Molecular Diagnostics. You will ﬁnd all the records from
around 280 presentations from various events in the past years
(2010–2015). We provide the presentations for FREE via movie
streaming technology in high quality, high resolution and perfect
sound quality in high speed.
Enjoy reading and watching.
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